Search results
1 lut 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
- Management of MRSA - IDSA
In seriously ill patients with suspected MRSA infection, a...
- Management of MRSA - IDSA
1 lut 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
3 lut 2021 · The primary aim of this guideline was to update, where appropriate, previous recommendations, taking into account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK.
14 lis 2022 · Given the clinical burden of MRSA bacteremia, clinicians need to have a comprehensive idea of the different treatment options available, both old and new, including the mechanism of resistance, efficacy, safety profiles, and cost-effectiveness.
1 mar 2018 · Directory of guidance on prevention and control of Meticillin-resistant Staphylococcus aureus (MRSA), published by ECDC, EU/EEA Member States, international and national agencies and professional societies.
For adults with infective endocarditis, intravenous vancomycin or daptomycin (6 mg per kg intravenously once per day for six weeks) is recommended. Some experts recommend higher dosages of ...
In seriously ill patients with suspected MRSA infection, a loading dose of 25-30 mg/kg (actual body weight) may be considered (CIII). Given risk of red man syndrome and possible anaphylaxis associated with large doses, consider prolonging infusion time 2 h and pre-medication with antihistamine .
